GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celon Pharma SA (FRA:8RP) » Definitions » EV-to-FCF

Celon Pharma (FRA:8RP) EV-to-FCF : -38.61 (As of Apr. 03, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Celon Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Celon Pharma's Enterprise Value is €317.11 Mil. Celon Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-8.21 Mil. Therefore, Celon Pharma's EV-to-FCF for today is -38.61.

The historical rank and industry rank for Celon Pharma's EV-to-FCF or its related term are showing as below:

FRA:8RP' s EV-to-FCF Range Over the Past 10 Years
Min: -4819.57   Med: -34.72   Max: 779.31
Current: -41.6

During the past 9 years, the highest EV-to-FCF of Celon Pharma was 779.31. The lowest was -4819.57. And the median was -34.72.

FRA:8RP's EV-to-FCF is ranked worse than
100% of 547 companies
in the Drug Manufacturers industry
Industry Median: 23.54 vs FRA:8RP: -41.60

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-03), Celon Pharma's stock price is €6.13. Celon Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €0.076. Therefore, Celon Pharma's PE Ratio (TTM) for today is 80.66.


Celon Pharma EV-to-FCF Historical Data

The historical data trend for Celon Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celon Pharma EV-to-FCF Chart

Celon Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -24.59 -65.12 513.35 -14.96 -17.03

Celon Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.52 -17.03 -30.26 -60.18 -41.60

Competitive Comparison of Celon Pharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Celon Pharma's EV-to-FCF falls into.


;
;

Celon Pharma EV-to-FCF Calculation

Celon Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=317.111/-8.213
=-38.61

Celon Pharma's current Enterprise Value is €317.11 Mil.
Celon Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celon Pharma  (FRA:8RP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Celon Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.13/0.076
=80.66

Celon Pharma's share price for today is €6.13.
Celon Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.076.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Celon Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Celon Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Celon Pharma Business Description

Traded in Other Exchanges
Address
Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

Celon Pharma Headlines

No Headlines